OP Asset Management Ltd Purchases New Shares in Illumina, Inc. $ILMN

OP Asset Management Ltd acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 1st quarter, Holdings Channel.com reports. The fund acquired 16,068 shares of the life sciences company’s stock, valued at approximately $1,981,000.

A number of other hedge funds have also bought and sold shares of ILMN. JPMorgan Chase & Co. grew its stake in shares of Illumina by 17.5% during the third quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock valued at $79,081,000 after buying an additional 124,246 shares during the last quarter. Elo Mutual Pension Insurance Co bought a new stake in shares of Illumina during the 3rd quarter worth approximately $2,319,000. Nordea Investment Management AB boosted its holdings in Illumina by 2,792.2% during the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after acquiring an additional 911,843 shares during the period. Capital World Investors boosted its holdings in Illumina by 20.0% during the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after acquiring an additional 3,331,542 shares during the period. Finally, Neo Ivy Capital Management bought a new position in Illumina in the 3rd quarter valued at $1,827,000. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ILMN shares. Guggenheim upped their price target on shares of Illumina from $170.00 to $180.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Barclays boosted their price objective on shares of Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research report on Wednesday. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a research note on Thursday, May 14th. Royal Bank Of Canada began coverage on shares of Illumina in a research note on Thursday, May 14th. They set an “outperform” rating and a $170.00 price target for the company. Finally, Evercore reaffirmed an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $146.00.

Insider Buying and Selling

In other news, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares in the company, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the transaction, the director directly owned 2,830,452 shares of the company’s stock, valued at approximately $463,146,860.76. The trade was a 7.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 1,003,769 shares of company stock worth $155,710,908 over the last quarter. Insiders own 2.90% of the company’s stock.

Illumina Price Performance

Shares of ILMN opened at $176.55 on Monday. The company has a 50 day moving average price of $149.62 and a 200-day moving average price of $137.73. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $182.84. The stock has a market capitalization of $26.71 billion, a PE ratio of 32.10, a PEG ratio of 3.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. Illumina’s revenue was up 4.8% compared to the same quarter last year. During the same period last year, the company posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities analysts predict that Illumina, Inc. will post 5.21 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.